ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

MD Anderson to buy Bellicum’s cell therapy plant

by Michael McCoy
February 1, 2020 | APPEARED IN VOLUME 98, ISSUE 5

 

The University of Texas MD Anderson Cancer Center will purchase Bellicum Pharmaceuticals’ approximately 5,500 m2 cell therapy facility in Houston, including manufacturing, office, and lab space, for $15 million. MD Anderson will operate the facility both for its own internal programs and to manufacture Bellicum’s GoCAR and other cell therapies for clinical trials and potentially early commercial supply. Bellicum says the deal will allow it to reduce expenses while keeping access to product supply.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment